Company / Shareholders' Equity
Protalix BioTherapeutics, Inc. Shareholders' Equity History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$43.2M
FY2025
5-year range
-$70.3M / $43.2M
FY2021-FY2025
Trend
+506.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity changed +506% YoY in FY2025, a notable deviation from the 9-year average annual change of +11%.
Based on SEC 10-K filings.
$43M in FY2025.
Improved from -$6M to $43M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity increased 506.1% year-over-year.
- Lowest shareholders' equity in the period was in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $43.2M | +506.1% |
| FY2024 | -$10.6M | -76.3% |
| FY2023 | -$6.0M | +77.7% |
| FY2022 | -$27.0M | +61.6% |
| FY2021 | -$70.3M | -33.0% |
| FY2020 | -$52.9M | -79.5% |
| FY2019 | -$29.5M | -370.9% |
| FY2017 | $10.9M | +119.6% |
| FY2016 | -$55.6M | -106.3% |
| FY2015 | -$26.9M | -702.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026